InflaRx (IFRX) Non Operating Income (2017 - 2026)
InflaRx's (IFRX) quarterly Non Operating Income came in at -$1.9 million in Q1 2026, up 61.67% year-on-year from -$1.2 million in Q1 2025, and down 172.95% quarter-over-quarter from $2.6 million in Q4 2025.
InflaRx (IFRX) Non Operating Income (2017 - 2026) Analysis & Trends
InflaRx has disclosed Non Operating Income across 10 years of filings, most recently posting -$1.9 million for Q1 2026.
- Non Operating Income for Q1 2026 came in at -$1.9 million, up 61.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (up 267.49% YoY), and the FY2025 annual result was $2.1 million, down 38.05% from the prior year.
- Non Operating Income came in at -$1.9 million for Q1 2026 at InflaRx, down from $2.6 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $9.3 million in Q4 2023 to a low of -$4.9 million in Q1 2025.
- The 5-year median for Non Operating Income is -$678124.0 (2022), against an average of $301211.2.
- Across the five-year window, Non Operating Income soared 2678.88% in 2023 and tumbled 686.06% in 2024, its largest moves.
- InflaRx's Non Operating Income stood at $334283.0 in 2022, then jumped by 2678.88% to $9.3 million in 2023, then sank by 37.03% to $5.8 million in 2024, then tumbled by 55.68% to $2.6 million in 2025, then tumbled by 172.95% to -$1.9 million in 2026.
- The last three Non Operating Income figures came in at -$1.9 million (Q1 2026), $2.6 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 9.35 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | -1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.89 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Dec 31, 2024 | 5.85 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | -1.67 Mn |
| Mar 31, 2024 | -3.08 Mn |
| Dec 31, 2023 | 9.29 Mn |
| Sep 30, 2023 | -4.03 Mn |
| Jun 30, 2023 | -1.80 Mn |
| Mar 31, 2023 | 524,857.71 |
| Dec 31, 2022 | 334,283.03 |
| Sep 30, 2022 | -678,123.97 |
| Jun 30, 2022 | -1.66 Mn |
| Mar 31, 2022 | -961,066.77 |
| Dec 31, 2021 | 2.02 Mn |
| Sep 30, 2021 | -799,145.23 |
| Jun 30, 2021 | 961,890.13 |